922 related articles for article (PubMed ID: 9506240)
1. 5-HT3 receptor antagonists for the prevention of chemotherapy-induced nausea and vomiting. A comparison of their pharmacology and clinical efficacy.
Gregory RE; Ettinger DS
Drugs; 1998 Feb; 55(2):173-89. PubMed ID: 9506240
[TBL] [Abstract][Full Text] [Related]
2. Palonosetron: a unique 5-HT3 receptor antagonist indicated for the prevention of acute and delayed chemotherapy-induced nausea and vomiting.
Rubenstein EB
Clin Adv Hematol Oncol; 2004 May; 2(5):284-9. PubMed ID: 16163194
[TBL] [Abstract][Full Text] [Related]
3. Tropisetron: an update of its use in the prevention of chemotherapy-induced nausea and vomiting.
Simpson K; Spencer CM; McClellan KJ
Drugs; 2000 Jun; 59(6):1297-315. PubMed ID: 10882164
[TBL] [Abstract][Full Text] [Related]
4. [Recent improvements in antiemetic therapy].
Roila F; Palladino MA; Ciccarese G; Basurto C
Tumori; 1997; 83(2 Suppl):S3-14. PubMed ID: 9235727
[TBL] [Abstract][Full Text] [Related]
5. Dolasetron. A review of its pharmacology and therapeutic potential in the management of nausea and vomiting induced by chemotherapy, radiotherapy or surgery.
Balfour JA; Goa KL
Drugs; 1997 Aug; 54(2):273-98. PubMed ID: 9257083
[TBL] [Abstract][Full Text] [Related]
6. Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double-blind, double-dummy, randomised, comparative phase III trial.
Saito M; Aogi K; Sekine I; Yoshizawa H; Yanagita Y; Sakai H; Inoue K; Kitagawa C; Ogura T; Mitsuhashi S
Lancet Oncol; 2009 Feb; 10(2):115-24. PubMed ID: 19135415
[TBL] [Abstract][Full Text] [Related]
7. A risk-benefit assessment of serotonin 5-HT3 receptor antagonists in antineoplastic therapy-induced emesis.
Perez EA
Drug Saf; 1998 Jan; 18(1):43-56. PubMed ID: 9466087
[TBL] [Abstract][Full Text] [Related]
8. Antiemetic medication for prevention and treatment of chemotherapy-induced nausea and vomiting in childhood.
Phillips RS; Friend AJ; Gibson F; Houghton E; Gopaul S; Craig JV; Pizer B
Cochrane Database Syst Rev; 2016 Feb; 2(2):CD007786. PubMed ID: 26836199
[TBL] [Abstract][Full Text] [Related]
9. Granisetron. A pharmacoeconomic evaluation of its use in the prophylaxis of chemotherapy-induced nausea and vomiting.
Plosker GL; Benfield P
Pharmacoeconomics; 1996 Apr; 9(4):357-74. PubMed ID: 10160110
[TBL] [Abstract][Full Text] [Related]
10. Comparison of two different intravenous serotonin antagonists used for chemotherapy-induced nausea and vomiting prophylaxis in patients treated with moderately emetogenic risk regimens: A retrospective analysis from a large academic medical center.
Gamble M; Carroll E; Wright GC; Glode AE
J Oncol Pharm Pract; 2020 Dec; 26(8):1964-1969. PubMed ID: 32633661
[TBL] [Abstract][Full Text] [Related]
11. Comparative review of 5-HT3 receptor antagonists in the treatment of acute chemotherapy-induced nausea and vomiting.
Hesketh PJ
Cancer Invest; 2000; 18(2):163-73. PubMed ID: 10705879
[TBL] [Abstract][Full Text] [Related]
12. Advances in use of the 5-HT3 receptor antagonists.
Walton SM
Expert Opin Pharmacother; 2000 Jan; 1(2):207-23. PubMed ID: 11249543
[TBL] [Abstract][Full Text] [Related]
13. 5-HT3-receptor antagonists: a review of pharmacology and clinical efficacy.
Cunningham RS
Oncol Nurs Forum; 1997 Aug; 24(7 Suppl):33-40. PubMed ID: 9282379
[TBL] [Abstract][Full Text] [Related]
14. Review of the preclinical pharmacology and comparative efficacy of 5-hydroxytryptamine-3 receptor antagonists for chemotherapy-induced emesis.
Perez EA
J Clin Oncol; 1995 Apr; 13(4):1036-43. PubMed ID: 7707101
[TBL] [Abstract][Full Text] [Related]
15. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and other antiemetics.
Hsu ES
Am J Ther; 2010; 17(5):476-86. PubMed ID: 20844345
[TBL] [Abstract][Full Text] [Related]
16. Use of dexamethasone with 5-HT3-receptor antagonists for chemotherapy-induced nausea and vomiting.
Perez EA
Cancer J Sci Am; 1998; 4(2):72-7. PubMed ID: 9532406
[TBL] [Abstract][Full Text] [Related]
17. Is ondansetron more effective than granisetron for chemotherapy-induced nausea and vomiting? A review of comparative trials.
Vrabel M
Clin J Oncol Nurs; 2007 Dec; 11(6):809-13. PubMed ID: 18063539
[TBL] [Abstract][Full Text] [Related]
18. Comparative safety and effectiveness of serotonin receptor antagonists in patients undergoing chemotherapy: a systematic review and network meta-analysis.
Tricco AC; Blondal E; Veroniki AA; Soobiah C; Vafaei A; Ivory J; Strifler L; Cardoso R; Reynen E; Nincic V; Ashoor H; Ho J; Ng C; Johnson C; Lillie E; Antony J; Roberts DJ; Hemmelgarn BR; Straus SE
BMC Med; 2016 Dec; 14(1):216. PubMed ID: 28007031
[TBL] [Abstract][Full Text] [Related]
19. Stratified administration of serotonin 5-HT3 receptor antagonists (setrons) for chemotherapy-induced emesis. Economic implications.
Sanchez LA; Holdsworth M; Bartel SB
Pharmacoeconomics; 2000 Dec; 18(6):533-56. PubMed ID: 11227393
[TBL] [Abstract][Full Text] [Related]
20. Progress in reducing nausea and emesis. Comparisons of ondansetron (Zofran), granisetron (Kytril), and tropisetron (Navoban).
Morrow GR; Hickok JT; Rosenthal SN
Cancer; 1995 Aug; 76(3):343-57. PubMed ID: 8625113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
